Home › Funds › KVP Capital Advisors, LP › PTGX

KVP Capital Advisors, LP position in PTGX

PROTAGONIST THERAPEUTICS INC · Health Care

KVP Capital Advisors, LP reported holding 53,000 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$6.5M, representing 4.77% of its reported portfolio and ranking #8 among its reported holdings. KVP Capital Advisors, LP has disclosed PTGX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)53.00K sh
Reported value held$6.50M
Portfolio Weight4.77%
First reportedQ4 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How KVP Capital Advisors, LP's PTGX position evolved

KVP Capital Advisors, LP first disclosed a stake in PTGX in Q4 2025 at 53,000 shares (US$4.6M). The position peaked in Q2 2026 at 53,000 shares, worth US$6.5M. Across 3 filings, KVP Capital Advisors, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 53,000 shares valued at US$6.5M.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 53.00K $4.63M New
Q1 2026 53.00K $5.59M Hold
Q2 2026 53.00K $6.50M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PTGX and 13F data

PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 49 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PTGX

All PTGX fund holders →

FAQ

How long has KVP Capital Advisors, LP held PTGX?

KVP Capital Advisors, LP has disclosed PTGX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is KVP Capital Advisors, LP's current position in PTGX?

As of Q2 2026, KVP Capital Advisors, LP holds 53.00K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $6.50M, representing 4.77% of its reported portfolio and ranking #8.

Has KVP Capital Advisors, LP been buying or selling PTGX?

In the latest 13F filing (Q2 2026), KVP Capital Advisors, LP held unchanged its position in PTGX. The position peaked in Q2 2026 at 53.00K shares.

Which other funds hold PTGX?

Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 49 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.